Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 8:12:580199.
doi: 10.3389/fnagi.2020.580199. eCollection 2020.

Circulating Exosome microRNAs as Diagnostic Biomarkers of Dementia

Affiliations
Review

Circulating Exosome microRNAs as Diagnostic Biomarkers of Dementia

Xiaoyu Dong et al. Front Aging Neurosci. .

Abstract

Dementia is a syndrome of acquired cognitive impairment that leads to a significant decline in a patient's daily life, ability to learn, and the ability to communicate with others. Dementia occurs in many diseases, including Alzheimer's disease (AD), dementia with Lewy bodies, frontotemporal dementia, and Parkinson's disease dementia (PDD). Although the analysis of biomarkers in the cerebrospinal fluid (CSF) and peripheral blood physicochemical analysis can indicate neurological impairment, there are currently no sensitive biomarkers for early clinical diagnosis of dementia or for identifying the cause of dementia. Previous studies have suggested that circulating micro (mi)RNAs may be used as biomarkers for diagnosing neurological disorders. However, miRNAs are susceptible to interference by other components in the peripheral circulation, bringing into question the diagnostic value of circulating miRNAs. Exosomes secreted by most cell types contain proteins, mRNAs, and miRNAs that are closely associated with changes in cellular functions. Exosome miRNAs (ex-miRNAs) are highly stable and resistant to degradation. Therefore, these may serve as useful biomarkers for the early clinical diagnosis of dementia. Here, we review studies of ex-miRNAs that commonly cause clinical dementia and explore whether ex-miRNAs may be used as early diagnostic biomarkers of dementia.

Keywords: biomarker; blood; cerebrospinal fluid; dementia; exosome miRNA.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Methodological aspects of circulating biomarker research and circulating exosome miRNAs as biomarkers for dementia disorders.

References

    1. Arena A., Iyer A. M., Milenkovic I., Kovacs G. G., Ferrer I., Perluigi M., et al. . (2017). Developmental expression and dysregulation of miR-146a and miR-155 in Down’s syndrome and mouse models of Down’s syndrome and Alzheimer’s disease. Curr. Alzheimer Res. 14, 1305–1317. 10.2174/1567205014666170706112701 - DOI - PubMed
    1. Arshad A. R., Sulaiman S. A., Saperi A. A., Jamal R., Mohamed Ibrahim N., Abdul Murad N. A. (2017). MicroRNAs and target genes as biomarkers for the diagnosis of early onset of Parkinson disease. Front. Mol. Neurosci. 10:352. 10.3389/fnmol.2017.00352 - DOI - PMC - PubMed
    1. Asselineau D., Benlhassan K., Arosio B., Mari D., Ferri E., Casati M., et al. . (2015). Interleukin-10 production in response to amyloid-β differs between slow and fast decliners in patients with Alzheimer’s Disease. J. Alzheimers Dis. 46, 837–842. 10.3233/jad-142832 - DOI - PubMed
    1. Baiardi S., Abu-Rumeileh S., Rossi M., Zenesini C., Bartoletti-Stella A., Polischi B., et al. . (2018). Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer’s disease pathology better than Aβ42 in rapidly progressive dementias. Ann. Clin. Transl. Neurol. 6, 263–273. 10.1002/acn3.697 - DOI - PMC - PubMed
    1. Barbagallo C., Mostile G., Baglieri G., Giunta F., Luca A., Raciti L., et al. . (2020). Specific signatures of serum miRNAs as potential biomarkers to discriminate clinically similar neurodegenerative and vascular-related diseases. Cell. Mol. Neurobiol. 40, 531–546. 10.1007/s10571-019-00751-y - DOI - PMC - PubMed

LinkOut - more resources